GRI Bio, Inc.
Market Cap
$231.77K
P/E Ratio
-0.02
EPS
$-121.80
Dividend Yield
0.00%
52-Week Range
$2.10 — $311.36
Volume
24.88K
Avg Volume
407.57K
Beta
-1.20
P/E (TTM)
-0.02
Forward P/E
—
PEG Ratio
-0.00
P/S (TTM)
0.01
P/B (TTM)
0.21
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-3.82%
ROA (TTM)
-1.38%
ROIC
—
Gross Margin
-0.00%
Operating Margin
-0.41%
Net Margin
—
Debt/Equity
0.01
Current Ratio
3.25
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.02%
EPS Growth (5Y)
-3.07%
Sales Growth (3Y)
-0.33%
Sales Growth (5Y)
-0.40%
EPS Est (This Year)
$-48.86
EPS Est (Next Year)
$-12.32
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$16.53
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
89.83K
Float
89.82K
Free Float %
99.99%
RSI (14)
9.47
SMA 20
$4.25
SMA 50
$13.68
SMA 200
$37.59
ATR (14)
0.63
Volatility (Week)
0.09%
Volatility (Month)
0.09%
Pattern
—
1 Day
+0.00%
1 Week
-9.47%
1 Month
-64.75%
3 Months
-95.09%
6 Months
-93.23%
1 Year
—
YTD
-69.52%
All-Time High
$311.36
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2023-04-24
Employees
3
CEO
W. Marc Hertz
Index Membership
—
Website
https://www.gribio.com
GRI Bio, Inc. (GRI) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $231.77K, a P/E ratio of -0.02, GRI is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare GRI against other stocks using dozens of fundamental and technical filters.
DRMA
Dermata Therapeutics, Inc.
$1.22
+1.67%
$831.50K
VRAX
Virax Biolabs Group Limited
$0.20
+8.74%
$880.11K
AGMB
AgomAb Therapeutics N.V. American Depositary Shares
$13.71
-4.23%
$342.75K
WINT
Windtree Therapeutics, Inc.
$0.02
+100.00%
$674.18K
ELAB
PMGC Holdings Inc.
$4.44
-8.26%
$78.48K
CMND
Clearmind Medicine Inc.
$0.75
+1.35%
$102.49K
GRI Bio, Inc. (GRI) has a trailing twelve-month (TTM) P/E ratio of -0.02. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, GRI Bio, Inc. (GRI) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
GRI Bio, Inc. (GRI) has a market capitalization of $231,767, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
GRI Bio, Inc. (GRI) has returned -69.52% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.